Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-05-16 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory disclosure requirement. This fits the definition of a 'Share Issue/Capital Change' (SHA) announcement.
2017-05-16 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 89% confidence The document is a company announcement detailing an increase in share capital through the exercise of employee warrants, listing the number of shares and subscription prices, and describing the subsequent listing and capital changes. This fits the definition of a Share Issue/Capital Change announcement.
2017-05-16 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim Report for the First Quarter of 2017' and contains substantive financial data, including revenue, operating expenses, operating income, and cash position for the specified period. Although it mentions that the full report is available as an attachment, the provided text itself contains the core financial results and analysis, distinguishing it from a mere publication announcement. Therefore, it is classified as an Interim/Quarterly Report. Q1 2017
2017-05-10 English
Genmab Announces Financial Results for the First Quarter of 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report for the First Quarter of 2017' and contains comprehensive financial statements, including consolidated key figures, income statements, balance sheets, cash flow statements, and notes to the financial statements. It is a 28-page report detailing the company's financial performance, outlook, and operational progress, which fits the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-10 English
Legal Proceedings Report 2017
Legal Proceedings Report Classification · 99% confidence The document is titled 'Company Announcement' and details a clinical trial update regarding a drug (daratumumab) and its collaboration with Janssen and the European Myeloma Network. It includes a date (April 28, 2017), company boilerplate information, contact details, and forward-looking statements. This format is characteristic of a general press release or regulatory disclosure made by a company to inform the market about significant operational or clinical developments, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a general announcement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), the most appropriate general category for non-standard regulatory disclosures is 'Regulatory Filings' (RNS), which serves as a broad category for company announcements not covered elsewhere.
2017-04-28 English
Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the initiation of a new Phase III clinical study for a drug (daratumumab). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a board change or dividend notice. As it is a general regulatory announcement regarding company operations and clinical trial progress, it falls under the 'Regulatory Filings' (RNS) category.
2017-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.